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Nonalcoholic fatty liver disease (NAFLD) isone of the most prevalent liver diseases inindustrialized countries, with approximately
30%-40% of adults suffering from NAFLD. Of those,
15%-20% will develop to its progressive entity nonal-
coholic steatohepatitis (NASH), a condition that may
further progress to liver ﬁbrosis and cirrhosis.(1)
Because insulin resistance and visceral obesity are
major contributors in the pathogenesis of NAFLD/
NASH, weight loss, exercise, and insulin-sensitizing
drugs are considered as primary treatment regimens.
Obeticholic acid, a farnesoid X nuclear receptor ago-
nist, previously approved for the treatment for primary
biliary cholangitis, is currently in a phase III trial for
patients with NASH ﬁbrosis. In the United States, no
effective treatments for NAFLD/NASH have been
approved by the U.S. Food and Drug Administration.
Potential therapeutic agents for NAFLD include
antidiabetic medications, such as pioglitazone, a perox-
isome proliferator-activated receptor gamma (PPARc)
agonist, and exenatide, a long-acting glucagon-like
peptide-1 (GLP-1) receptor agonist. GLP-1 is derived
from the proglucagon molecule. In pancreatic a cells,
the proglucagon molecule is processed to glucagon,
which increases blood glucose levels. In the gut,
GLP-1 and GLP-2 are produced from the same pro-
glucagon molecule. Interestingly, GLP-1 suppresses
blood glucose levels by stimulating pancreatic b cells to
secrete insulin, which is in contrast to glucagon.(2,3)
Because the mechanism of action of GLP-1 receptor
agonists is to stimulate insulin secretion to improve
insulin resistance and sensitivity, exenatide has been
shown to reverse steatohepatitis and is thus a potential
therapeutic agent.(2,4) The protease dipeptidyl peptide-
4 has been shown to degrade native GLP-1. Notably,
exenatide degrades dipeptidyl peptide-4 to maintain
the levels of endogenous GLP-1. Although GLP-1-
mediated insulin secretion in pancreatic b cells has
been well documented, the role of GLP-1 signaling
and exenatide’s mechanism of action, which is thought
to include the induction of carcinoembryonic antigen-
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related cell adhesion molecule 1 (CEACAM1), in
hepatocytes is poorly understood. CEACAM1
expression is transcriptionally regulated by insulin and
lipids, and CEACAM1 regulates insulin clearance in
hepatocytes. A better understanding of the underlying
mechanisms of hepatic insulin clearance by the GLP-
1–CEACAM1 axis would be highly relevant to target-
ing and ultimately preventing the progression of
NAFLD.
Insulin is released in a pulsatile manner by pancre-
atic b cells. When insulin reaches the liver through
portal circulation, the insulin receptor tyrosine kinase
in hepatocytes is phosphorylated and then initiates the
phosphorylation of its substrates, such as CEACAM1.
Once phosphorylated, CEACAM1 promotes
receptor-mediated insulin uptake into clathrin-coated
vesicles in hepatocytes to be degraded, leading to an
extraction of 50% of insulin.(1) Previous studies have
shown that phosphorylated and internalized CEA-
CAM1 binds fatty acid synthase (FASN), an enzyme
that catalyzes the formation of palmitic acid from
malonyl-coenzyme A in de novo lipogenesis.(1,5) By
binding to FASN, CEACAM1 decreases FASN
enzymatic activity and severely restricts hepatic de novo
lipogenesis. Studies have also shown that under
hyperinsulinemic conditions, the pulsatility of insulin
secretions decreases, in effect limiting insulin signaling
and downstream CEACAM1 phosphorylation. Subse-
quently, the suppressive effect of FASN is removed,
leading to hyperinsulinemia-driven lipogenesis.(1,5)
In the present issue of Hepatology Communications,
Ghadieh et al.(6) provide new evidence that a GLP-1
agonist, exenatide, improves hepatic steatosis by regu-
lating hepatic insulin clearance through induction of
CEACAM1 in mice.
This study ﬁrst presented that high-fat diet (HFD)
feeding reduced expression of CEACAM1 in hepato-
cytes. Because CEACAM1 contributes to hepatic
insulin clearance, this ﬁnding suggests that NAFLD is
associated with reduced insulin clearance. Ghadieh
et al. demonstrate that exenatide treatment dramati-
cally increased expression of CEACAM1 in hepato-
cytes in mice fed a HFD diet and induced elevation of
insulin internalization in hepatocytes from wild-type
mice; this induced elevation of insulin uptake was not
observed in CEACAM1–/– hepatocytes. Their results
strongly suggest that exenatide treatment upregulates
insulin uptake and subsequent clearance through
CEACAM1 induction. The authors further per-
formed a deeper analysis of the regulatory mechanism
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FIG. 1. Schematic of the role of exe-
natide and CEACAM1 in insulin
uptake and de novo lipogenesis. Exena-
tide binding to the GLP-1 receptor
(GLP-1R) activates GLP-1R signal-
ing, initiating PPARc-mediated tran-
scription of CEACAM1 mRNA.
CEACAM1 activation simultaneously
inhibits de novo lipogenesis by binding
FASN and increases insulin uptake
and clearance, preventing progression
to NAFLD. Abbreviations: DPP-4,
dipeptidyl peptidase-4; GLP-1R,
GLP-1 receptor; in, insulin; mRNA,
messenger RNA; P, phosphorylation.
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of exenatide-mediated CEACAM1 induction and
found that exenatide increased CEACAM1 promoter
activity through an increase in PPARc. Their chroma-
tin immunoprecipitation assay clearly demonstrated
that ligated PPARc bound to the CEACAM1 pro-
moter region in cells treated with rosiglitazone, a
PPARc agonist, or exenatide, indicating that PPARc
or exenatide-induced PPARc contributes to up-
regulation of CEACAM1 promoter activity and tran-
scription. Interestingly, insulin and exenatide synergis-
tically increased Ceacam1 promoter activity, while
exenatide plus rosiglitazone did not show synergistic
action in Ceacam1 promoter activity. This suggests that
exenatide-induced Ceacam1 transcription is mediated
through PPARc (Fig. 1).
The effect of exenatide on CEACAM1 induction
and insulin clearance in primary hepatocytes has been
conﬁrmed by an in vivo animal model. In both wild-
type and CEACAM1–/– mice, exenatide treatment
suppressed food intake and induced acute-phase insu-
lin secretion, which were also observed in both regular
and HFD feeding conditions. These ﬁndings suggest
that CEACAM1 is not important in pancreatic b cells
and the central nervous system and that the role of
CEACAM1 seems to be limited in hepatocytes, which
further suggests that hepatic CEACAM1 does not
inﬂuence food intake and insulin secretion from b
cells. Another explanation is that the dysfunction of
insulin clearance did not affect GLP-1-mediated insu-
lin secretion and reduction of body weight. This may
require further study to investigate whether these
events are truly independent. Consistently, exenatide
treatment recovered hepatic CEACAM1 expression
along with its phosphorylation, which resulted in full
clearance of insulin. This recovered insulin clearance
by exenatide was blunted in CEACAM1–/– mice,
demonstrating that exenatide-mediated in vivo insulin
clearance is dependent on induction of CEACAM1.
Importantly, worsened insulin and glucose tolerance
tests by HFD feeding were mitigated by exenatide
treatment. Increased hepatic triglyceride levels and
steatosis by HFD feeding were also improved by exe-
natide treatment. One of the molecular mechanisms
that Ghadieh and co-authors identiﬁed is that induced
CEACAM1 forms a complex with FASN to decrease
FASN activity, which suppresses hepatic steatosis.
These therapeutic effects of exenatide were abolished
in CEACAM1–/– mice, demonstrating the importance
of CEACAM1 in exenatide-mediated improvement
of the systemic metabolic phenotype and NAFLD.
Additionally, exenatide showed an anti-inﬂammatory
effect by demonstrating lowered messenger RNA lev-
els of interleukin-1b, interleukin-6, and interferon-c.
Exenatide has been shown to suppress appetite and
increase glucose-stimulated insulin secretion. These
effects are mediated through activation of GLP-1
receptor signaling in the central nervous system and
pancreatic b cells. An important ﬁnding of this study
is the positive effect that exenatide has on insulin clear-
ance in hepatocytes, which has not been demonstrated
previously. Moreover, exenatide can suppress hepatic
de novo lipogenesis through binding of CEACAM1 to
FASN, which inhibits FASN activity. In addition to
the improvement of insulin secretion and sensitivity,
enhanced insulin clearance and inhibition of de novo
lipogenesis by exenatide cumulatively participate in
preventing the development of NAFLD. Although
CEACAM1 plays an important role in insulin clear-
ance, the reduced hepatic triglyceride levels by CEA-
CAM1 are mediated through inhibition of FASN
activity. This might be independent of CEACAM1-
mediated promotion of insulin clearance.
GLP-1 receptor activation has been established as a
powerful incretin and anorexigenic peptide in the pan-
creas and central nervous system; however, this study
investigated GLP-1 receptor signaling in hepatocytes.
Although the authors revealed that GLP-1-mediated
enhancement of insulin clearance is associated with the
improvement of NAFLD, the precise mechanism of
how improved insulin clearance improves hepatic stea-
tosis and inﬂammation in NAFLD has not been well
studied. Ghadieh and colleagues showed exenatide
improved hepatic steatosis through CEACAM1, which
is induced through PPARc. However, PPARc is also
known to enhance lipogenesis.(7) This discrepancy
might be explained by the fact that PPARc has different
effects between liver and adipose tissues. A better
understanding of the molecular mechanisms of hepatic
insulin clearance may provide novel therapies that affect
the development of NAFLD; this may potentially pro-
vide various options for treating NAFLD in patients.
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